233P Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) + endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials

ML-3 and -7 demonstrated a significant OS benefit maintenance/improvement of QOL with RIB + ET vs in pts HR+/HER2? ABC. We evaluated the association -7. In ML-3, postmenopausal were treated fulvestrant (FUL) or FUL alone. This analysis included NSAI cohort ML-7, which peri/premenopausal was assessed EORTC QLQ-C30. A responder performed based on published minimal clinically important differences change from baseline to group as improvers/maintainers (responder) non-improvers/non-maintainers (non-responder). The percentage responders summarized for each visit by treatment arm who lived longer shorter (OS cutoffs: 39.2 mo ML-3; 33.1 ML-7). -7, greater living had improved/maintained global health status (GHS), pain, fatigue, diarrhea either (tx) group. GHS seen PBO shorter, (Table). tx but not observed those shorter; this trend regardless line tx. There consistent ML-7 shorter. pain mainly second-line population longer.Table: 233PPt population, %Mean % GHSML-3All (n=631)RIB (n=422)PBO (n=209)3226Pts (n=316)RIB (n=219)PBO (n=97)4538Pts (n=315)RIB (n=203)PBO (n=112)2120ML-7 (NSAI cohort)All (n=478)RIB (n=242)PBO (n=236)3526Pts (n=241)RIB (n=135)PBO (n=106)4534Pts (n=237)RIB (n=107)PBO (n=130)3226 Open table new tab more over course both trials, generally associated improvement/maintenance compared alone, longer.